Following a UNICEF order worth ₹127 crore, Panacea Biotec shares increased 5% to ₹456.25. The stock has seen substantial growth in recent times, up 225% over the last six months and 167 per cent year-to-date (YTD).

Shares of Panacea Biotec are now locked in an upper circuit of 5% at ₹454.90. With today's surge, the stock has rallied over 160% so far in 2024. Over the last 12 months, the stock is up 163%.

As per the company's filing, the United Nations International Children's Emergency Fund (UNICEF) awarded the company to supply 115 million doses of bivalent oral polio vaccine (bOPV) in Africa/Asia

Panacea Biotec announced that it was awarded a contract from United Nations International Children's Emergency Fund (UNICEF) to supply 115 million doses of its bivalent oral polio vaccine (bOPV) worth ₹127 crore.